Mineralocorticoid R/NR3C2 Antibody (NR3C2/4900) [PE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-26968PE
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry-Paraffin
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG1 kappa Clone # NR3C2/4900
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Mineralocorticoid R/NR3C2 Antibody (NR3C2/4900) [PE]
Immunogen
Recombinant fragment (around aa601-673) of human Mineralocorticoid R/NR3C2 protein
Localization
Nucleus
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for Mineralocorticoid R/NR3C2 Antibody (NR3C2/4900) [PE]
Application
Recommended Usage
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Mineralocorticoid R/NR3C2
Long Name
Mineralocorticoid Receptor
Alternate Names
MineralocorticoidR, MLR, NR3C2
Gene Symbol
NR3C2
Additional Mineralocorticoid R/NR3C2 Products
Product Documents for Mineralocorticoid R/NR3C2 Antibody (NR3C2/4900) [PE]
Product Specific Notices for Mineralocorticoid R/NR3C2 Antibody (NR3C2/4900) [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...